[68Ga]Ga-NECT-224 PET/CT显示ADC治疗中进展性尿路上皮癌Nectin-4表达增加
一例64岁转移性尿路上皮癌患者在接受Nectin-4靶向抗体偶联药物恩诺单抗维多汀联合帕博利珠单抗治疗前后行[68Ga]Ga-NECT-224 PET/CT。治疗3个月后CT随访显示肾上腺转移进展,再次PET/CT显示多个新发病灶伴强烈Nectin-4表达,提示该显像可可视化Nectin-4异质性表达并潜在指导治疗。
要点
- [68Ga]Ga-NECT-224 PET/CT可无创可视化尿路上皮癌Nectin-4表达。
- ADC治疗进展后病灶仍可保留强烈Nectin-4表达。
- 该显像有潜力指导Nectin-4靶向治疗决策。
核心结论
- [68Ga]Ga-NECT-224 PET/CT有潜力可视化尿路上皮癌Nectin-4表达的异质性并指导治疗。
- 对细胞毒治疗耐药但保留靶点表达的患者,需考虑诊疗一体化策略。
研究设计与样本
- 单例病例报告:64岁男性转移性尿路上皮癌患者,原发右肾盂。
- 在恩诺单抗维多汀联合帕博利珠单抗治疗前及进展后行[68Ga]Ga-NECT-224 PET/CT。
主要发现
- ADC治疗3个月后CT随访显示肾上腺转移进展。
- 再次[68Ga]Ga-NECT-224 PET/CT显示多个新发病灶伴强烈Nectin-4表达。
临床怎么用
- 可考虑用[68Ga]Ga-NECT-224 PET/CT评估Nectin-4表达以辅助治疗决策。
- ADC治疗进展后仍可评估靶点表达,探索诊疗一体化策略。
局限性
- 仅为单例病例报告,结论需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 64-year-old man with metachronous metastatic urothelial carcinoma originating from the right renal pelvis underwent nectin-4-targeted [ 68 Ga]Ga-NECT-224 PET/CT prior to initiation of nectin-4-targeted antibody-drug conjugate (ADC) therapy with enfortumab-vedotin (PADCEV), in combination with pembrolizumab. A CT follow-up after 3 months of ADC therapy showed a progressive adrenal metastasis. Subsequent [ 68 Ga]Ga-NECT-224 PET/CT restaging revealed multiple new lesions with intense nectin-4 expression. This case illustrates the potential of [ 68 Ga]Ga-NECT-224 PET/CT to visualize heterogeneous nectin-4 expression, its potential in therapy guidance, and highlights the need for theranostic strategies in patients retaining target expression despite cytotoxic therapy resistance.
引用
- Hoberück S, Banek S, Krönke T, et al. [ 68 Ga]Ga-NECT-224 PET/CT Shows Increasing Nectin-4 Expression in Progressive Urothelial Carcinoma Under ADC-Therapy With Enfortumab-Vedotin. Clin Nucl Med. 2026. PMID: 42257446. doi:10.1097/RLU.0000000000006528
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。